Yourgene Health PLC - Manchester, England-headquartered molecular diagnostics firm - Says it has won two further tenders for national framework contracts, valued at a total of GBP4 billion. Yourgene says it was successful with its tenders under Public Health England's National Microbiology Framework for lot 2, covering research & development goods and services, and lot 3, covering manufacturing, product development and commercialisation. Lot 2 is a GBP1.5 billion framework to be satisfied over two years by multiple successful bidders, while lot 3 is a GBP2.5 billion framework over two years with 9 suppliers appointed.
The PHE tender was opened in November last year and sought to appoint suppliers to a multi-lot national microbiology framework agreement. Yourgene has been successful in all four of these lots and is one of only three companies to do so.
"Over the last year we have built up an infectious disease business with an impressive testing capacity and a best-in-class product, and have done so without taking our focus away from our core business", says Yourgene Chief Executive Lyn Rees.
"We are now well positioned to compete for the next wave of contracts under this framework, particularly as one of only three companies successful in all four lots. We believe this has been the right approach to deliver value to our shareholders as we continue to deliver year-on-year revenue growth and position ourselves strongly in both the private and government testing markets over the next two years."
Current stock price: 14.45p, up 4.3% on Monday afternoon
Year-to-date change: down 2.0%
By Will Paige; willpaige@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
